Sorafenib for the treatment of advanced renal cell carcinoma

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7271-7278

  Kane, Robert C ^a   Farrell, Ann T ^a   Saber, Haleh ^a   Tang, Shenghui ^a   Williams, Gene ^a   Jee, Josephine M ^a   Liang, Chengyi ^a   Booth, Brian ^a   Chidambaram, Nallaperumal ^a   Morse, David ^a   Sridhara, Rajeshwari ^a   Garvey, Patricia ^a   Justice, Robert ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEXTROMETHORPHAN; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; MIDAZOLAM; OMEPRAZOLE; PLACEBO; RECOMBINANT INTERLEUKIN 2; SORAFENIB; TAMOXIFEN; VINBLASTINE;

ADJUVANT THERAPY; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; HAIR LOSS; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SENSORY NEUROPATHY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG EVALUATION; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; PLACEBOS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33846260566     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1249     Document Type: Article

References (16)

1. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
2. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
4. Robert C, Faivre S, Raymond E, Armand J, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005; 143:313-4.
5. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6:S55-7.
6. Krown SE. Interferon treatment of renal cell carcinoma. Cancer 1987;59:647-51.
7. Muss HB. The role of biological response modifiers in metastatic renal cell carcinoma. Semin Oncol 1988;15: 30-4.
8. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-7.
9. Pyrhonen S, Salminen M, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17: 2859-67.
10. Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Group Francais d'Immunotherape. J Clin Oncol 1999;17: 2039-43.
11. Negrier S, Perol D, Ravaud C, et al. Do cytokines improve survival in metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Proc Am Soc Clin Oncol 2005;23:380s, LBA4511.
12. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; Jan 25(1): CD001425.
13. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:1188-94.
14. Atzpodien J, Kirchner H, Illiger H J, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85:1130-6.
15. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
16. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. EORTC Genitourinary Group: radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-70.